# Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Source: https://onco.cc/trials/nct06883526/  
OnCo record `nct06883526` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gecacitinib in non-Hodgkin lymphoma, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.

## Summary

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma is a phase 1/2 interventional study registered as NCT06883526 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 60 participants planned, started 2025-05-16 and due to reach its primary completion in 2027-04. Interventions recorded: ZG005 for Injection and Gecacitinib Hydrochloride Tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06883526
- Phase: 1/2
- Setting: A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
- Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06883526: https://clinicaltrials.gov/study/NCT06883526

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Gecacitinib](https://onco.cc/drugs/gecacitinib/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)

---
JSON: https://onco.cc/api/v1/entities/nct06883526.json